Hinsch Claire Leist, Venkata Jagadish Kummetha, Hsu Tien, Dammai Vincent
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29401, USA.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29401, USA.
Cancers (Basel). 2023 Dec 14;15(24):5837. doi: 10.3390/cancers15245837.
How human FGFR1 localizes to the PM is unknown. Currently, it is assumed that newly synthesized FGFR1 is continuously delivered to the PM. However, evidence indicates that FGFR1 is mostly sequestered in intracellular post-Golgi vesicles (PGVs) under normal conditions. In this report, live-cell imaging and total internal reflection fluorescence microscopy (TIRFM) were employed to study the dynamics of these FGFR1-positive vesicles. We designed recombinant proteins to target different transport components to and from the FGFR1 vesicles. Mouse embryoid bodies (mEBs) were used as a 3D model system to confirm major findings. Briefly, we found that Rab2a, Rab6a, Rab8a, RalA and caveolins are integral components of FGFR1-positive vesicles, representing a novel compartment. While intracellular sequestration prevented FGFR1 activation, serum starvation and hypoxia stimulated PM localization of FGFR1. Under these conditions, FGFR1 C-terminus acts as a scaffold to assemble proteins to (i) inactivate Rab2a and release sequestration, and (ii) assemble Rab6a for localized activation of Rab8a and RalA-exocyst to deliver the receptor to the PM. This novel pathway is named Regulated Anterograde RTK Transport (RART). This is the first instance of RTK regulated through control of PM delivery.
人类成纤维细胞生长因子受体1(FGFR1)如何定位于质膜尚不清楚。目前,人们认为新合成的FGFR1会持续被转运至质膜。然而,有证据表明,在正常情况下,FGFR1大多被隔离在细胞内的高尔基体后囊泡(PGV)中。在本报告中,我们采用活细胞成像和全内反射荧光显微镜(TIRFM)来研究这些FGFR1阳性囊泡的动态变化。我们设计了重组蛋白,以靶向FGFR1囊泡的不同转运成分。小鼠胚胎体(mEB)被用作三维模型系统来证实主要发现。简而言之,我们发现Rab2a、Rab6a、Rab8a、RalA和小窝蛋白是FGFR1阳性囊泡的组成部分,代表了一个新的区室。虽然细胞内隔离会阻止FGFR1的激活,但血清饥饿和缺氧会刺激FGFR1定位于质膜。在这些条件下,FGFR1的C末端充当支架来组装蛋白质,以(i)使Rab2a失活并解除隔离,以及(ii)组装Rab6a以局部激活Rab8a和RalA-外排复合体,从而将受体转运至质膜。这条新途径被命名为受调控的正向受体酪氨酸激酶转运(RART)。这是通过控制质膜转运来调控受体酪氨酸激酶的首个实例。